1. Enhanced desmosome assembly driven by acquired high-level desmoglein-2 promotes phenotypic plasticity and endocrine resistance in ER + breast cancer.
- Author
-
Liu B, Liu Y, Yang S, Ye J, Hu J, Chen S, Wu S, Liu Q, Tang F, Liu Y, He Y, Du Y, Zhang G, Guo Q, and Yang C
- Subjects
- Humans, Female, Animals, Mice, Fulvestrant pharmacology, Antineoplastic Agents, Hormonal pharmacology, Receptors, Estrogen metabolism, Cell Line, Tumor, Phenotype, Plakophilins metabolism, Plakophilins genetics, Cell Plasticity drug effects, Xenograft Model Antitumor Assays, MCF-7 Cells, Gene Expression Regulation, Neoplastic, gamma Catenin, Desmoglein 2 metabolism, Desmoglein 2 genetics, Breast Neoplasms pathology, Breast Neoplasms genetics, Breast Neoplasms metabolism, Breast Neoplasms drug therapy, Drug Resistance, Neoplasm, Desmosomes metabolism, Wnt Signaling Pathway
- Abstract
Acquired resistance to endocrine treatments remains a major clinical challenge. In this study, we found that desmoglein-2 (DSG2) plays a major role in acquired endocrine resistance and cellular plasticity in ER
+ breast cancer (BC). By analysing the well-established fulvestrant-resistant ER+ BC model using single-cell RNA-seq, we revealed that ER inhibition leads to a specific increase in DSG2 in cancer cell populations, which in turn enhances desmosome formation in vitro and in vivo and cell phenotypic plasticity that promotes resistance to treatment. DSG2 depletion reduced tumorigenesis and metastasis in fulvestrant-resistant xenograft models and promoted fulvestrant efficiency. Mechanistically, DSG2 forms a desmosome complex with JUP and Vimentin and triggers Wnt/PCP signalling. We showed that elevated DSG2 levels, along with reduced ER levels and an activated Wnt/PCP pathway, predicted poor survival, suggesting that a DSG2high signature could be exploited for therapeutic interventions. Our analysis highlighted the critical role of DSG2-mediated desmosomal junctions following antiestrogen treatment., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)- Published
- 2024
- Full Text
- View/download PDF